Biotech9 months ago
Vertex Strengthens its Position in Nephrology and Buys Alpine Immune Sciences for $4.9 Billion
Vertex announced plans to acquire Alpine Immune Sciences for $4.9 billion, primarily for its experimental drug povetacicept to treat IgA nephropathy. Vertex will pay $65 per...